ALK-ABELLO B A/S revenue breakdown overview

ALK-ABELLO B A/S revenue for the last year amounted to 5.54 B DKK, the most of which — 2.85 B DKK — came from its highest performing source at the moment, Sublingual Immunotherapy-Tablets, the year earlier bringing 2.30 B DKK. The greatest contribution to the revenue figure was made by Europe — last year it brought ALK-ABELLO B A/S 2.13 B DKK, and the year before that — 1.86 B DKK.